Transgene
Biotechnology ResearchBas-Rhin, France201-500 Employees
Cancer immunotherapy Transgene (Euronext: TNG) is a biotechnology company focused on designing and developing novel immunotherapies for the treatment of cancer.
Recent Talent Acquisitions Transgene has been strategically strengthening its leadership team by appointing key executives like Lucie Larguier as Chief Financial Officer and Christelle Schwoerer as Chief Human Resources Officer. Leveraging these new hires could provide opportunities to pitch innovative cancer immunotherapies to potential partners or investors seeking expertise in the field.
Expansion in Cancer Vaccine Development Transgene's focus on developing a head and neck cancer vaccine, in collaboration with NEC, showcases a commitment to advancing cancer immunotherapy solutions. Highlighting this cutting-edge development could position the company favorably for collaborations with healthcare institutions or pharmaceutical companies looking to invest in novel oncology treatment options.
Financial Recognition and Future Investments Receiving the 'Investment for the Future' award from Bpifrance underscored Transgene's innovative approach and potential for growth. This recognition could be leveraged in sales pitches to attract additional funding or partnerships with organizations that value technological advancement and long-term sustainability.
Promotion of Key Personnel The promotion of Lucie Larguier to Vice President Corporate Communications and Investor Relations signifies a focus on enhancing stakeholder relations and bolstering the company's public image. Building on this promotion, Transgene could explore sales opportunities by showcasing strong leadership and communication strategies to attract potential investors or collaborators seeking transparency and credibility.
Market Differentiation through Strategic Collaborations Collaborating with renowned partners like NEC for vaccine development positions Transgene as a frontrunner in the biotechnology research industry. Emphasizing these strategic alliances in sales propositions could appeal to potential clients or investors looking for companies with a solid network and a track record of successful collaborations in the competitive biotech landscape.
Transgene uses 8 technology products and services including Site Kit, WordPress, CookieYes, and more. Explore Transgene's tech stack below.
Transgene Email Formats | Percentage |
Last@transgene.fr | 64% |
FirstLast@transgene.fr | 25% |
First.Last@transgene.fr | 9% |
F.Last@transgene.fr | 2% |
Biotechnology ResearchBas-Rhin, France201-500 Employees
Cancer immunotherapy Transgene (Euronext: TNG) is a biotechnology company focused on designing and developing novel immunotherapies for the treatment of cancer.
Transgene has raised a total of $16M of funding over 4 rounds. Their latest funding round was raised on Jul 17, 2023 in the amount of $16M.
Transgene's revenue is in the range of $50M$100M
Transgene has raised a total of $16M of funding over 4 rounds. Their latest funding round was raised on Jul 17, 2023 in the amount of $16M.
Transgene's revenue is in the range of $50M$100M